Login to Your Account



Antisoma, Novartis Expand ASA404 into Lung Cancer

By Nuala Moran


Wednesday, July 23, 2008
LONDON - Antisoma plc said its partner Novartis AG will take ASA404, a vascular disrupting agent, into a second pivotal Phase III trial in the second-line treatment of non-small-cell lung cancer, a move that will open up a bigger market if the trial is positive. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription